Last Updated : December 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tarceva | Erlotinib | Cancer, Lung , non-small cell | List with clinical criteria and/or conditions | Complete | ||
Targin | Oxycodone HCI / naloxone HCI | Pain, moderate to severe and relief of opioid-induced constipation | Do not list | Complete | ||
Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | |||
Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | ||
Tavneos | avacopan | Antineutrophil cytoplasmic antibody-associated vasculitis | Do not reimburse | Complete | ||
TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | |||
TBC | filgrastim | Cancelled | ||||
TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | |||
TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
TBC | etonogestrel | Prevention of pregnancy | Withdrawn |